Welcome to the international HTA database

Showing [21936 Records] Selected Records [0 Hits] [Clear]

Year	Source	Title
2022	NIHR Health Technology Assessment programme	Development and evaluation of machine learning methods in whole body magnetic resonance imaging with diffusion weighted imaging for staging of patients with cancer (MAchine Learning In whole Body Oncology, MALIBO)
2022	NIHR Health Technology Assessment programme	Endometrial scratch to increase live birth rates in women undergoing first-time in vitro fertilisation: RCT and systematic review
2022	Agency for Care Effectiveness (ACE)	Revivent TC transcatheter ventricular enhancement system for ischemic heart failure
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Polatuzumab Vedotin (new therapeutic indication: diffuse large B-cell lymphoma (DLBCL), combination with rituximab, cyclophosphamide, doxorubicin and prednisone (R-CHP))]
2022	NIHR Health Technology Assessment programme	FEMME trial: Randomised trial of treating Fibroids with either Embolisation or MyoMectomy to measure the Effect on quality of life
2022	Agency for Care Effectiveness (ACE)	Vagus nerve stimulation with the VITARIA System for heart failure with reduced ejection fraction
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Tisagenlecleucel (new therapeutic indication: follicular lymphoma, pretreated patients)]
2022	Agency for Care Effectiveness (ACE)	Caption guidance to guide image acquisition in point-of-care echocardiography for patients with cardiovascular disease
2022	NIHR Health Technology Assessment programme	A randomised, multi-stage phase II/III study of standard first-line therapy (sunitinib or pazopanib) comparing temporary cessation with allowing continuation, in the treatment of locally advanced and/or metastatic renal cancer (the STAR trial)
2022	Agency for Care Effectiveness (ACE)	The PrecivityAD test for the prognosis of Alzheimer's disease
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Voxelotor (haemolytic anaemia in sickle cell disease, monotherapy or combination with hydroxycarbamide, ≥ 12 years)]
2022	NIHR Health Technology Assessment programme	Fast-Forward: a randomised clinical trial testing a 1-week course of curative whole breast radiotherapy against a standard 3-week schedule in terms of local cancer control and late adverse effects in women with early breast cancer
2022	Basque Office for Health Technology Assessment (OSTEBA)	[Autism spectrum disorder: scientific evidence on its detection, diagnosis and treatment]
2022	Agency for Care Effectiveness (ACE)	Artificial intelligence and its clinical applications
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Avapritinib (new therapeutic indication: systemic mastocytosis, after at least 1 prior therapy)]
2022	Basque Office for Health Technology Assessment (OSTEBA)	[Image-guided spinal fusion technology]
2022	Agency for Care Effectiveness (ACE)	3D printing and its clinical applications
2022	Basque Office for Health Technology Assessment (OSTEBA)	[Temporary percutaneous circulatory support devices for the treatment and prevention of cardiogenic shock: analysis of efficacy, effectiveness and safety]
2022	Agency for Care Effectiveness (ACE)	Overview of clinical applications of telemedicine
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Tebentafusp (uveal melanoma, HLA-A*02:01-positive)]
2022	Agency for Care Effectiveness (ACE)	Bilateral cochlear implants for children with severe-to-profound sensorineural hearing loss in both ears
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Glucarpidase (reduction of toxic plasma methotrexate concentrations; aged 28 days and older)]
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Idebenone (reassessment after the deadline: Leber's Hereditary Optic Neuropathy)]
2022	Agency for Healthcare Research and Quality (AHRQ)	Diagnostic errors in the emergency department: a systematic review
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of knowledge: amyotrophic lateral sclerosis with or without frontotemporal dementia NGS panel]
2022	Scottish Health Technologies Group (SHTG)	The Psychology Adding Value – Epilepsy Screening (PAVES) and early intervention for children and young people with epilepsy at risk of mental health problems
2022	Center for Drug Evaluation (CDE)	Patient involvement in the health technology assessment process in Taiwan
2022	NIHR Health Technology Assessment programme	Gastric Bypass, adjustable gastric Banding or Sleeve gastrectomy surgery to treat severe and complex obesity: a multi-centre randomised controlled trial (The By-Band-Sleeve Study)
2022	NIHR Health Technology Assessment programme	POSNOC - POsitive Sentinel NOde: adjuvant therapy alone versus adjuvant therapy plus Clearance or axillary radiotherapy: A randomised controlled trial of axillary treatment in women with early stage breast cancer who have metastases in one or two sentinel nodes
2022	Agency for Care Effectiveness (ACE)	Percutaneous vertebral augmentation systems for treating patients with vertebral compression fractures
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Voretigene Neparvovec (reassessment after the deadline: inherited retinal dystrophy)]
2022	Scottish Health Technologies Group (SHTG)	A national radiology information system (RIS) for Scotland: perceived benefits and constraints to implementation
2022	NIHR Health Technology Assessment programme	The PRmotion Of Physical activity through structured Education with differing Levels of ongoing Support for those with prediabetes (PROPELS): randomised controlled trial in a diverse multi-ethnic community
2022	The Federal Joint Committee (G-BA)	[Pharmaceutical Directive/Annex XII: Somatrogon (growth disturbance due to growth hormone deficiency, ≥ 3 to < 18 years]
2022	NIHR Health Technology Assessment programme	E-FREEZE: a randomised controlled trial evaluating the clinical and cost-effectiveness of a policy of freezing all embryos followed by thawed frozen embryo transfer, compared with a policy of fresh embryo transfer in women undergoing in-vitro fertilization
2022	Agency for Care Effectiveness (ACE)	Continuous subcutaneous insulin infusion therapy for treating type 1 diabetes
2022	NIHR Health Technology Assessment programme	Treatment of Advanced Glaucoma Study (TAGS): a multicentre randomised controlled trial comparing primary medical treatment with primary trabeculectomy for people with newly diagnosed advanced glaucoma
2022	NIHR Health Technology Assessment programme	RCT of clinical and cost-effectiveness of drug coated balloons, drug eluting stents and balloon angioplasty with bail-out bare metal stent revascularisation strategies for severe limb ischaemia due to femoro-popliteal disease: BASIL-3 (Balloon vs Stenting in Severe Ischaemia of the Leg)
2022	NIHR Health Technology Assessment programme	Accuracy and cost-effectiveness of dynamic contrast enhanced computed tomography in the characterisation of solitary pulmonary nodules
2022	Agency for Healthcare Research and Quality (AHRQ)	Evaluation of mental health mobile applications
2022	Malaysian Health Technology Assessment (MaHTAS)	Transcutaneous oxygen pressure monitoring (TcPO2)
2022	Agency for Healthcare Research and Quality (AHRQ)	Improving rural health through telehealth-guided provider-to-provider communication
2022	Penn Medicine Center for Evidence-based Practice (CEP)	VTE chemoprophylaxis for patients undergoing elective spinal surgery
2022	Malaysian Health Technology Assessment (MaHTAS)	Sublingual immunotherapy (SLIT) for atopy (allergic rhinitis, eczema and asthma)
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Calcifediol (secondary hyperparathyroidism) - Benefit assessment according to §35a Social Code Book V]
2022	Agency for Healthcare Research and Quality (AHRQ)	Infection prevention and control for the emergency medical services and 911 workforce
2022	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Patients with hip fracture from low-impact trauma: clinical management of anti-osteoporotic pharmacological treatment to prevent new fractures]
2022	Penn Medicine Center for Evidence-based Practice (CEP)	Video camera-assisted or electromagnetic placement of enteral feeding tubes
2022	Malaysian Health Technology Assessment (MaHTAS)	Mesenchymal stem cells for retinitis pigmentosa and other degenerative retina disease
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Isoflurane (sedation of mechanically ventilated patients) - Benefit assessment according to §35a Social Code Book V]
2022	Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS)	[Efficacy and safety of the pilates method in selected clinical conditions]
2022	NIHR Health Technology Assessment programme	Helicobacter eradication to prevent ulcer bleeding in aspirin users: a large simple randomised controlled trial (HEAT)
2022	Penn Medicine Center for Evidence-based Practice (CEP)	Pneumocystis jirovecii pneumonia (PJP) prophylaxis
2022	Health Technology Wales (HTW)	Left atrial appendage occlusion in patients with atrial fibrillation
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Burosumab (X-linked hypophosphataemia) - Benefit assessment according to §35a Social Code Book V]
2022	Agency for Care Effectiveness (ACE)	Bone conduction hearing implants for patients with conductive or mixed hearing loss
2022	Health Technology Wales (HTW)	Continuous topical oxygen therapy to treat people with chronic non-healing and complex diabetic foot ulcers
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Burosumab (X-linked hypophosphataemia, = 18 years) - Benefit assessment according to §35a Social Code Book V]
2022	NIHR Health Technology Assessment programme	Sensory integration therapy for children with autism and sensory processing difficulties: the SenITA RCT
2022	Agency for Care Effectiveness (ACE)	Active middle ear implants for patients with hearing loss
2022	Health Sciences Institute in Aragon (IACS)	Efficacy, safety and efficiency of sentinel lymph node magnetic localisation techniques in breast cancer
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Duvelisib (chronic lymphocytic leukaemia) - Benefit assessment according to §35a Social Code Book V]
2022	The Regional Health Technology Assessment Centre (HTA-centrum)	Progesterone, cerclage, pessary, or acetylsalicylic acid for prevention of preterm birth in singleton and multifetal pregnancies
2022	Agency for Care Effectiveness (ACE)	Bone conduction hearing implants for patients with single sided deafness
2022	WorkSafeBC	Dry needling for lateral elbow pain
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Duvelisib (follicular lymphoma) - Benefit assessment according to §35a Social Code Book V]
2022	Agency for Care Effectiveness (ACE)	Coronary intravascular lithotripsy for patients with severely calcified, stenotic de novo coronary artery
2022	WorkSafeBC	Efficacy and/or effectiveness of treatments for lateral epicondylitis - barbotage and ultrasonic tenotomy
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Dupilumab (severe asthma with type 2 inflammation) - Benefit assessment according to §35a Social Code Book V]
2022	WorkSafeBC	Fat grafting for nerve padding
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Casirivimab/imdevimab (COVID-19) - Benefit assessment according to §35a Social Code Book V]
2022	WorkSafeBC	Intravenous ketamine for PTSD and treatment-resistant depression
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Lenvatinib (endometrial carcinoma) - Addendum to Commission A21-162]
2022	Medical Services Advisory Committee (MSAC)	Genetic testing for childhood hearing impairment
2022	NIHR Health Technology Assessment programme	The RAPID-CTCA trial (Rapid Assessment of Potential Ischaemic Heart Disease with CTCA) The role of early CT Coronary Angiography in the evaluation, intervention and outcome of patients presenting to the Emergency Department with suspected or confirmed Acute Coronary Syndrome
2022	Agency for Care Effectiveness (ACE)	Denosumab for treating osteoporosis and glucocorticoid-associated bone loss
2022	WorkSafeBC	Sweat lodge usage as treatment for depression or other psychological disorders
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pembrolizumab (endometrial carcinoma) - Addendum to Commission A21-164]
2022	Medical Services Advisory Committee (MSAC)	Two testing options for determining eligibility for access to Pharmaceutical Benefits Schedule-subsidised aducanumab in patients with early stage Alzheimer disease
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Glucarpidase (toxic MTX plasma concentrations) - Assessment according to §35a SGB V (1), Sentence 11]
2022	Norwegian Institute of Public Health (NIPH)	Surgical procedures for treatment of obesity: health technology assessment
2022	Health Technology Wales (HTW)	Closed loop systems for the management of type 1 diabetes mellitus in adults and children
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Voxelotor (sickle cell disease) - Assessment according to §35a (para. 1, sentence 11) Social Code Book V]
2022	NIHR Health Technology Assessment programme	Targeting vascular adhesion protein-1 (VAP-1) for the treatment of liver fibrosis: a study of efficacy and mechanisms in patients with primary sclerosing cholangitis (PSC)
2022	Penn Medicine Center for Evidence-based Practice (CEP)	Organizational strategies to improve or promote healthcare worker wellness
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Relugolix/estradiol/norethisterone (uterine fibroid) - Benefit assessment according to §35a Social Code Book V]
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pembrolizumab (small bowel cancer) - Benefit assessment according to §35a Social Code Book V]
2022	NIHR Health Technology Assessment programme	Optimal utilisation of biologic drugs in Behcet's Disease: a randomised controlled trial of infliximab vs alpha interferon, with genotyping and metabolomic profiling, towards a stratified medicines approach to treatment
2022	Agency for Care Effectiveness (ACE)	Non-vitamin K antagonist oral anti-coagulation agents (NOACs) for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation
2022	Norwegian Institute of Public Health (NIPH)	First trimester-screening for the development of preeclampsia with the use of an algorithm: a health technology assessment
2022	Health Technology Wales (HTW)	Photobiomodulation for the prevention and treatment of oral mucositis and radiation dermatitis associated with cancer treatment
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Pembrolizumab (bile cancer) - Benefit assessment according to § 35a SGB V]
2022	Institut national d'excellence en sante et en services sociaux (INESSS)	[State of practice: solid organ transplantation – Section 2 - overview of liver transplantation in Québec]
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Empagliflozin (heart failure) - Addendum to Commission A21-93]
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Nivolumab (urothelial carcinoma, adjuvant) - Addendum to Commission A22-53]
2022	NIHR Health Technology Assessment programme	Allopurinol and cardiovascular outcomes in patients with ischaemic heart disease
2022	Health Technology Wales (HTW)	Wearable cardioverter-defibrillators for people at risk of cardiac death
2022	Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)	[Nivolumab (oesophageal carcinoma, combination with chemotherapy) - Addendum to Commission A22-54]
2022	Agency for Healthcare Research and Quality (AHRQ)	Management of infantile epilepsies
2022	NIHR Health Technology Assessment programme	VIdeo assisted thoracoscopic lobectomy versus conventional Open LobEcTomy for lung cancer, a multi-centre randomised controlled trial with an internal pilot. The VIOLET Study